PMID- 33894089
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1399-3038 (Electronic)
IS  - 0905-6157 (Linking)
VI  - 32
IP  - 7
DP  - 2021 Oct
TI  - Newer-generation antihistamines and the risk of adverse events in children: A 
      systematic review.
PG  - 1533-1558
LID - 10.1111/pai.13522 [doi]
AB  - BACKGROUND: H1-antihistamines (AHs) are widely used for the treatment of allergic 
      diseases, being one of the most commonly prescribed classes of medications in 
      pediatrics. Newer-generation AHs are associated with fewer adverse effects 
      compared with first-generation AHs. However, their relative harms in the 
      pediatric population still need scrutiny. METHODS: We performed a systematic 
      review of randomized controlled trials (RCTs), which included comparisons of 
      safety parameters between an orally administered newer-generation AH and another 
      AH (first- or second-generation), montelukast, or placebo in children aged 
      </=12 years. We searched MEDLINE and CENTRAL, independently extracted data on study 
      population, interventions, adverse events (AEs), and treatment discontinuations, 
      and assessed the methodologic quality of the included RCTs using the Cochrane's 
      risk of bias tool. RESULTS: Forty-five RCTs published between 1989 and 2017 met 
      eligibility criteria. The majority of RCTs included school-aged children with 
      allergic rhinitis and had a follow-up period of up to a month. Four RCTs reported 
      serious AEs in patients receiving a newer-generation AH, but only two patients 
      experienced a possibly drug-related serious AE. The occurrence of AEs, 
      drug-related AEs, and treatment discontinuations due to AEs varied between RCTs. 
      Most AEs reported were of mild intensity. Indirect evidence indicates that 
      cetirizine is more sedating than the other newer-generation AHs. CONCLUSION: Our 
      findings confirm that newer-generation AHs have a favorable safety and 
      tolerability profile. However, we could not draw firm conclusions regarding the 
      comparative safety profile of the newer-generation AHs due to the paucity of 
      head-to-head RCTs, variation in definitions and reporting of AEs, and short 
      follow-up duration.
CI  - (c) 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Miligkos, Michael
AU  - Miligkos M
AUID- ORCID: 0000-0001-8021-2780
AD  - Society of Junior Doctors, Athens, Greece.
AD  - First Department of Pediatrics, "Aghia Sophia" Children's Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
FAU - Dakoutrou, Maria
AU  - Dakoutrou M
AD  - Society of Junior Doctors, Athens, Greece.
AD  - First Department of Pediatrics, "Aghia Sophia" Children's Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
FAU - Statha, Eleni
AU  - Statha E
AD  - Society of Junior Doctors, Athens, Greece.
FAU - Theochari, Nikoletta A
AU  - Theochari NA
AD  - Society of Junior Doctors, Athens, Greece.
FAU - Mavroeidi, Ilektra Antonia
AU  - Mavroeidi IA
AD  - Society of Junior Doctors, Athens, Greece.
FAU - Pankozidou, Iotaoanna
AU  - Pankozidou Iota
AD  - Society of Junior Doctors, Athens, Greece.
FAU - Papaconstadopoulos, Irene
AU  - Papaconstadopoulos I
AD  - Department of Pediatrics, Unterberg Children's Hospital at Monmouth Medical 
      Center, Long Branch, NJ, USA.
FAU - Papadopoulos, Nikolaos G
AU  - Papadopoulos NG
AD  - Allergy Department, Second Pediatric Clinic, National and Kapodistrian University 
      of Athens, Athens, Greece.
AD  - Division of Infection, Immunity and Respiratory Medicine, School of Biological 
      Sciences, The University of Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20210520
PL  - England
TA  - Pediatr Allergy Immunol
JT  - Pediatric allergy and immunology : official publication of the European Society 
      of Pediatric Allergy and Immunology
JID - 9106718
RN  - 0 (Histamine Antagonists)
RN  - 0 (Histamine H1 Antagonists)
RN  - YO7261ME24 (Cetirizine)
SB  - IM
MH  - Cetirizine/adverse effects
MH  - Child
MH  - *Histamine Antagonists
MH  - *Histamine H1 Antagonists
MH  - Humans
OTO - NOTNLM
OT  - adverse events
OT  - antihistamines
OT  - children
OT  - pediatrics
OT  - systematic review
EDAT- 2021/04/25 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/04/24 17:05
PHST- 2021/04/01 00:00 [revised]
PHST- 2020/12/01 00:00 [received]
PHST- 2021/04/13 00:00 [accepted]
PHST- 2021/04/25 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/04/24 17:05 [entrez]
AID - 10.1111/pai.13522 [doi]
PST - ppublish
SO  - Pediatr Allergy Immunol. 2021 Oct;32(7):1533-1558. doi: 10.1111/pai.13522. Epub 
      2021 May 20.